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Introduction: In the United Kingdom, the self-administration of 
prescribed medicines by hospitalized patients has been supported by 
pharmaceutical and nursing bodies. Suggested benefits of self-admin-
istration include greater patient knowledge about their medicines, 
improved concordance with treatment, and increased patient satisfac-
tion. We wished to assess the proportion of medicines administered 
by hospitalized patients and to describe the patient and drug factors 
associated with self-administration.
Patients (or Materials) and Methods: We used data from University 
Hospitals Birmingham NHS Foundation Trust, which uses a locally 
developed electronic prescribing and medication administration sys-
tem known as PICS (Prescribing, Information and Communication 
System). We extracted data from every drug prescription and admin-
istration recorded from January 1, 2012, to December 31, 2012. 
The data were analyzed to ascertain the degree to which patients 
administered their medicines in the hospital. Drug and patient data 
were also extracted to determine the association between these fac-
tors and self-administration.
Results: In the 12-month period analyzed, 45,115 patients were 
admitted to the hospital. During this time period, 657,230 drug pre-
scriptions were recorded, of which 5.8% (38,583) were administered 
by the patient at least once during the course of the prescription. The 
drugs most commonly self-administered were paracetamol, salbu-
tamol, and nystatin. The majority of medicines (14,797 [38.4%]) 
administered by the patient was in a tablet form. Almost two thirds 
(65.4%) of prescriptions identified as the patient’s own were admin-
istered by the patient. The self-administration of medicines occurred 
at least once in a significantly greater proportion of male patients 
(28.9% compared with 27.6%; P = 0.01).
Conclusion: During the 1-year period examined, < 6% of prescribed 
medicines were administered by the patient. These data suggest that 
the focused promotion of self-administration to appropriate patients 
may be necessary. However, it remains unknown to what extent self-
administration could or should be increased, as an evaluation of 
the benefits and potential harms of patients administering their own 
medicines has not yet been undertaken. Further work is also nec-
essary to evaluate the role of electronic prescribing and medicine 
administration systems in supporting the self-administration of medi-
cines in patients where it is safe and appropriate.
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Introduction: Timely administration of medicines in hospital is essen-
tial for optimizing treatment and avoiding unnecessary disruption to 
the patient’s usual routine. The time a medicine is administered to 
a patient can be compared with the time it was due, and used as a 
marker for the quality of medicines provision in a hospital setting.
Patients (or Materials) and Methods: The Prescribing Information 
and Communication System (PICS) is an electronic prescribing and 
medicines administration system in place at the University Hospitals 
Birmingham NHS Foundation Trust. Data from the PICS system 
feeds a database that has been used to audit the timeliness of medi-
cation administration within the Trust. Data are provided for all 
medicines administered > 30 minutes before or > 90 minutes after 
the due time, classified as “not on time” (and noncompliant with 
guidance) and shown on the clinical dashboard. To investigate this 
issue further, data were extracted for a 4-week period between August 
and September 2012 for all “regular” and “one-off” doses (excluding 
infusions). For each administration, the prescribed “due time” was 
noted as well as time that administration was documented to occur.
Results: The audit data demonstrate that just under one half of 
all medicines were administered within the 2-hour time window 
of the prescribed due time. However further analysis of the data 
showed that the majority of medicines were prescribed to be 
administered at 1 of 6 specific times during the day, despite there 
only being 4 main medicine administration rounds carried out 
in any 24-hour period. Specific issues were noted; for example, 
many medicines were prescribed to be administered at midday, a 
time protected for patient meal times and therefore not feasible 
for medicine administration. Documented administration times 
often varied significantly from due times around these round 
intervals.
Conclusion: Overall, the hospital showed poor performance on the 
timely administration of medicines, which was never been much bet-
ter than 50% compliance. Further analysis has shown that for most 
clinical areas, only 4 medicine administration rounds occur, despite 
the prescribed due times of medicines being spread more widely. The 
due times of medicines produced from electronic system defaults and 
their subsequent administration were never designed with this sort 
of monitoring in mind. Capturing these data from the electronic 
prescribing system has highlighted the need to align system design 
with clinical practice.
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Introduction: Safety signals regarding drug effects on cardiac con-
ductivity have been found after the approval of medicines, despite 
evidence suggesting that they could be deemed safe during develop-
ment. Such a discrepancy may be caused by the known differences 
between real-life conditions and the so-called clinical trial population, 
which represents a subset of the target patient population, as defined 
by the many inclusion and exclusion criteria in clinical protocols. No 
formal quantitative method is available to assess the implications of 
differences betwen experimental conditions and therapeutic use of 
the drug. This study demonstrates the relevance of pharmacokinetic-
pharmacodynamic (PKPD) relationships to characterize drug-induced 
QTc-interval prolongation and to assess the implications discrepan-
cies between clinical trials and real life conditions.
Patients (or Materials) and Methods: d,l-sotalol data from healthy 
subjects and from the Rotterdam Study cohort were used as paradigm 
compound to assess treatment response in a Phase I setting and in 
real-life situation, respectively. Using not-trial-simulation principles 
and nonlinear mixed effects modeling, drug-induced effects were esti-
mated across populations to discriminate the potential implications 
of other relevant factors.
Results: Inclusion criteria were shown to restrict the representa-
tiveness of the trial population compared with real-life conditions. 
A significant part of the typical patient population was excluded 
from trials based on weight and baseline QT-interval measurements. 
Relative risk was statistically different between sotalol users with 
and without heart failure, hypertension, diabetes, and myocardial 
infarction. Although drug-induced effects do cause an increase in 
relative risk of QT interval prolongation, the presence of diabetes 
represented an increase in relative risk from 4.0 to 6.5, whereas for 
myocardial infarction it increased to 15.5 (P < 0.01).
Conclusion: Our results show that drug-induced effects on QTc-
interval do not fully explain the distribution of QTc values observed 
in the population. The increased prevalence of high QTc values in a 
real-life population can be assigned to comorbidities and concomitant 
medications. This discrepancy substantiates the need to account for 
these factors when evaluating cardiovascular risk of novel medicinal 
products. Moreover, the concept of not-in-trial simulations can be 
used as a tool for risk management, integrating pharmacokinetic-
pharmacodynamic relationships as the basis for discriminating 
drug-specific properties from other relevant factors in noncontrolled 
settings.
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Introduction: The clinical pharmacist has recently been involved in 
clinical work as a member of the Infectious Disease Committee (IDC) 
to optimize the appropriate use of antibiotics. The objective of this 
study is to evaluate the contribution of the clinical pharmacist in this 
multidisciplinary team.
Patients (or Materials) and Methods: A 5-month prospective study 
in a private hospital of 150 beds. The antibiotic treatment of each 
patient was reviewed by the clinical pharmacist, within the first 24 
hours after prescription, to detect/prevent Drug-Related Problems 
(DRP): adverse drug reactions, irrational drug utilization, and thera-
peutic failure. Furthermore, a pharmacotherapeutic follow-up was 
made until hospital discharge. The clinical pharmacist called the 
physician to make a recommendation when DRP were detected or 
suspected. Patient medical records and laboratory and microbiologi-
cal reports were used as sources of information. Creatinine clearance 
was calculated with the Crockcroft-Gault equation. Patient’s demo-
graphic data, description of pharmacologic interventions, and their 
acceptance were registered daily in a specific database.
Results: The study included 112 patients with a mean age of 76.3 
(15.1) years (10-99); 57 were women (50.9%). The clinical pharma-
cist made 163 pharmacologic interventions (range, 1–11 interven-
tions per patient), 42 (25.8%) having previously been agreed on 
with the other members of the IDC. The description of these inter-
ventions was as follows: drug choice and therapeutic de-escalation 
(n = 20 [12.3%]), excessive duration of antibiotic therapy (n = 22 
[13.5%]), sequential therapy (n = 23 [14.1%]), and dose adjust-
ment due to pharmacokinetic/pharmacodynamic parameters (n = 
18, 11%), kidney dysfunction (n = 69 [42.3%]) or obesity (n = 11 
[6.8%]). These drugs were penicillins (n = 48 [29.4%]), quinolones 
(n = 46 [28.2%]), carbapenems (n = 16 [9.8%]), cephalosporins 
(n = 16 [9.8%]), aminoglycosides (n = 7, 4.3%), oxazolidinones (n = 
5 [3.1%]), macrolides (n = 4 [2.5%]) and others (n = 21 [12.9%]). 
Intravenous administration was the main route (n = 142 [87.1%]) 
while oral administration was used in few cases (n = 21 [12.9%]). 
Finally, 133 (81.6%) pharmacologic interventions were accepted.
Conclusion: The contribution of the clinical pharmacist in the multi-
disciplinary team is becoming increasingly valuable and may improve 
the quality of antibiotic use. The high acceptance of this work seems 
to show that multidisciplinary teams are needed, with the objective 
that patients receive the safest and most effective pharmacological 
treatment as possible.
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